DEFA14A: Arrowhead Pharmaceuticals Addresses Proxy Advisor Concerns Over Director Independence

Arrowhead Pharmaceuticals supplements its proxy statement to address concerns raised by ISS and Glass Lewis regarding the independence of director Dr. Douglass Given and announces changes to board committee assignments.

Summary

• Arrowhead Pharmaceuticals has issued a supplement to its 2024 Notice of Annual Meeting and Proxy Statement to address concerns raised by proxy advisory firms ISS and Glass Lewis.
• The firms recommended voting against the election of Dr. Douglass Given due to his classification as a non-independent director, stemming from his brother's former executive role at the company.
• While Arrowhead disagrees with the five-year lookback period used by ISS and Glass Lewis for independence determinations (Nasdaq rules use a three-year lookback), the company has taken steps to address the concerns.
• Dr. Douglass Given has been removed from the Nomination Committee and the Compensation Committee.
• Dr. Michael Perry, an independent director, has been appointed as the Lead Director of the Board and as a member of the Compensation Committee.
• The company recommends stockholders vote FOR the election of Dr. Given.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are concerns raised by proxy advisors, the company is taking proactive steps to address them. The outcome of the shareholder vote remains uncertain.

Positives

• Arrowhead is proactively addressing concerns raised by proxy advisory firms.
• The company is taking steps to avoid even the appearance of a conflict of interest by removing Dr. Given from key committees.
• An independent director, Dr. Michael Perry, has been appointed as Lead Director and to the Compensation Committee.

Negatives

• ISS and Glass Lewis have raised concerns about the independence of a key director.
• The disagreement between Arrowhead and the proxy advisory firms could influence shareholder voting decisions.

Risks

• Shareholder votes may be influenced by the recommendations of ISS and Glass Lewis.
• The company's reputation could be affected by the perception of a lack of board independence.

Management Comments

• The disinterested members of our Board considered this information and determined that Dr. Douglass Given is an independent director under Nasdaq rules.
• We recommend stockholders vote FOR the election of Dr. Given.

Industry Context

This announcement reflects the increasing scrutiny on corporate governance and board independence, with proxy advisory firms wielding significant influence over shareholder voting.

Comparison to Industry Standards

• The disagreement highlights the different standards used by Nasdaq (3-year lookback) versus ISS and Glass Lewis (5-year lookback) for determining director independence.
• Many companies face similar challenges in balancing family relationships with independence requirements, particularly in founder-led or family-influenced businesses.
• Companies like Regeneron, where Leonard Schleifer's wife serves on the board, have faced similar scrutiny regarding director independence.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will be impacted by the board's composition and governance practices.
• Employees may be indirectly affected by the company's governance and reputation.

Next Steps

• Shareholders will vote on the election of directors at the Annual Meeting on March 14, 2024.

Key Dates

Keywords

proxy statement, director election, independence, ISS, Glass Lewis, board structure, corporate governance, Arrowhead Pharmaceuticals